Replies to post #419399 on NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

The TLD is not for managing the stock price, the surest way to cause massive problems and headaches for actually monetizing this at the end.

As for updates, they’ve told us the process. Expectations for intermediate updates about where should not be expected, IMHO. If I were in their shoes I would do exactly what they are doing. People who miss out, it’s unfortunate, but that is not and should not be their main concern.

[HappyLibrarian]

I would say we would have support around 75 cents and maybe higher than that. It's a nice round number and there are fundamental differences between now and the last time we were in the 20 cent range like the endpoint changes in Europe and also data lock.

It is very hard to argue that NWBO is worth more than $1 a share when we have not received a clear update in a very long time, NWBO has a bad history of finding new ways to delay things and we are in uncharted waters where there are no clear milestones for at least some potential news. The ASM is pretty much whenever NWBO wants it to be and ASCO is in June 2022.

The idea that management is absolved of any responsibility to try and support existing shareholders and that they should just put all chips on TLD, which they keep delaying and delaying is not reasonable. Not every shareholder can afford to keep holding especially with nothing positive visible on the horizon and that is not due to being 'weak hands' 'disloyal' or anything. Sometimes, as several shareholders here have noted, life happens. How much better it would have been if news had come before life happened? Well the longer they stretch things out, the more chances, more shareholders get the short end of the stick.